Donald Trump Has Stake In Hydroxychloroquine Drugmaker: Report
The president has repeatedly touted the anti-malaria drug as a coronavirus treatment despite a lack of medical evidence.
President Donald Trump reportedly owns a stake in a company that produces hydroxychloroquine, the anti-malaria drug he has repeatedly touted as a coronavirus treatment even though his experts say there’s no strong evidence it works.
Trump “has a small personal financial interest” in Sanofi, the French drugmaker that makes Plaquenil, the brand-name version of hydroxychloroquine, The New York Times reported Monday.
In addition, Sanofi’s largest shareholders include a mutual fund company run by major Republican donor Ke
n Fisher, the paper said. Trump’s three family trusts, as of last year, each had investments in a mutual fund whose largest holding was Sanofi, according to the Times. Commerce Secretary Wilbur Ross also had ties to the drugmaker, the Times reported.
Trump’s “assertiveness” in promoting the drug contrary to the recommendation of top health experts “has raised questions about his motives,” the Times noted.
No comments:
Post a Comment